Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 51

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Summary

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2017, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Brain Tumor, Hematological Tumor, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection and Liver Transplant Rejection.

Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

- The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects

- The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview 6
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment 14
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc 18
Hookipa Biotech AG 18
Immunomic Therapeutics Inc 18
Vakzine Projekt Management GmbH 19
Vaximm AG 19
VBI Vaccines Inc 20
Vical Inc 20
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles 21
ASP-0113 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CyMVectin - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HB-101 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PepVax - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Triplex - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VBI-1901 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
VPM-2001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
VXM-65 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products 38
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products 39
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones 40
Featured News & Press Releases 40
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 40
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 40
May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus 41
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 41
Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections 42
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 42
Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood 43
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 44
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 44
Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 45
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 45
Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine 46
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 46
Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 47
Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Astellas Pharma Inc, H2 2017 18
Pipeline by Hookipa Biotech AG, H2 2017 18
Pipeline by Immunomic Therapeutics Inc, H2 2017 19
Pipeline by Vakzine Projekt Management GmbH, H2 2017 19
Pipeline by Vaximm AG, H2 2017 19
Pipeline by VBI Vaccines Inc, H2 2017 20
Pipeline by Vical Inc, H2 2017 20
Dormant Projects, H2 2017 38
Discontinued Products, H2 2017 39

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16
  • 2017 Top 5 Cytokines Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 22-Sep-2017        Price: US 4960 Onwards        Pages: 165
    "This report will be delivered in 2-3 business days after the order is placed." The Global Cytokines market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Cytokines in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Cytokines Players in each region, with sales, p......
  • 2017-2022 China Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCare Phar......
  • 2017-2022 Global Top Countries Cytokines Market Report
    Published: 22-Sep-2017        Price: US 4960 Onwards        Pages: 165
    "This report will be delivered in 2-3 business days after the order is placed." The Global Cytokines market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Cytokines in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East an......
  • 2017-2022 India Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCare Phar......
  • 2017-2022 Japan Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCare Phar......
  • 2017-2022 Malaysia Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Malaysia market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer HealthCar......
  • 2017-2022 Philippines Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Philippines market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer Hea......
  • 2017-2022 United States Cytokines Market Report (Status and Outlook)
    Published: 22-Sep-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Cytokines market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include - AbbVie - Johnson & Johnson - GlaxoSmithKline - Novartis - Roche - Pfizer - Sanofi - Bayer......
  • North America Antibody Services Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Sep-2017        Price: US 4480 Onwards        Pages: 124
    Antibody services include competitively priced packages and purification options for antibody production. Service Providers offer support for different types and steps of antibody production—from peptide design, synthesis, and carrier protein conjugation to animal immunization, serum collection, or hybridoma fusion, titer analysis, and final antibody purification. They also immunize with recombinant proteins or protein fragments provided by the customers(or expressed and purified in labs using c......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs